Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Introduction
This analysis examines the current position and future outlook for Dainippon Sumitomo in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase
Benchmark Dainippon Sumitomo's performance against key rivals in the ethical pharmaceutical sector

Evaluate the corporate impact of the merger of Dainippon and Sumitomo

Investigate what strategies are open for Dainippon Sumitomo to build growth in the face of its mature portfolio and weak pipeline

Introduction
Disease management has failed to gain significant traction within the pharmaceutical industry, yet market survey data shows that demand for disease management services and tools is high among both physicians and consumers. Companies interested in investing in disease management must consider the preferences and types of these tools that are most likely to attract physicians and patients.

Reasons to Purchase
Assess and compare physician and consumer attitudes about disease management tools and services in different regions
Identify the disease management tools and services that are preferred by consumers and healthcare professionals
Identify obstacles to the uptake of disease management tools and services, from the perspectives of both physicians and consumers